69 related articles for article (PubMed ID: 17195453)
21. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
Koschny R; Holland H; Sykora J; Haas TL; Sprick MR; Ganten TM; Krupp W; Bauer M; Ahnert P; Meixensberger J; Walczak H
Clin Cancer Res; 2007 Jun; 13(11):3403-12. PubMed ID: 17545549
[TBL] [Abstract][Full Text] [Related]
22. Hyperthermic isolated perfusion with tumor necrosis factor-alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcoma: the experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO).
Di Filippo F; Giacomini P; Rossi CR; Santinami M; Garinei R; Anzà M; Deraco M; Botti C; Perri P; Cavaliere F; Di Angelo P; Sofra C; Sperduti I; Pasqualoni R; Di Filippo S; Corrias F; Armenti A; Ferraresi V
In Vivo; 2009; 23(2):363-7. PubMed ID: 19414428
[TBL] [Abstract][Full Text] [Related]
23. [Chemotherapy protocol "8 drugs in 1 day" in patients with recurrent malignant glioma].
Jeremić B; Grujicić D; Matović M
Srp Arh Celok Lek; 1994; 122(3-4):73-5. PubMed ID: 17972813
[TBL] [Abstract][Full Text] [Related]
24. TNF expressed by tumor-associated macrophages, but not microglia, can eliminate glioma.
Nakagawa J; Saio M; Tamakawa N; Suwa T; Frey AB; Nonaka K; Umemura N; Imai H; Ouyang GF; Ohe N; Yano H; Yoshimura S; Iwama T; Takami T
Int J Oncol; 2007 Apr; 30(4):803-11. PubMed ID: 17332918
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of high vs low dose TNF-isolated limb perfusion for locally advanced soft tissue sarcoma.
Nachmany I; Subhi A; Meller I; Gutman M; Lahat G; Merimsky O; Klausner JM
Eur J Surg Oncol; 2009 Feb; 35(2):209-14. PubMed ID: 18295442
[TBL] [Abstract][Full Text] [Related]
26. Intratumoral administration of tumor necrosis factor-alpha for malignant gliomas--two case reports.
Yamasaki T; Moritake K; Paine JT; Fukuda M; Ohta F; Naitoh H
Neurol Med Chir (Tokyo); 1994 Apr; 34(4):216-20. PubMed ID: 7520543
[TBL] [Abstract][Full Text] [Related]
27. HSV-1 amplicon-mediated post-transcriptional inhibition of Rad51 sensitizes human glioma cells to ionizing radiation.
Saydam O; Saydam N; Glauser DL; Pruschy M; Dinh-Van V; Hilbe M; Jacobs AH; Ackermann M; Fraefel C
Gene Ther; 2007 Aug; 14(15):1143-51. PubMed ID: 17495946
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882).
Hildebrand J; Gorlia T; Kros JM; Afra D; Frenay M; Omuro A; Stupp R; Lacombe D; Allgeier A; van den Bent MJ;
Eur J Cancer; 2008 Jun; 44(9):1210-6. PubMed ID: 18248979
[TBL] [Abstract][Full Text] [Related]
29. A multivariate analysis of patients with brain tumors treated with ATN-RNA.
Wyszko E; Rolle K; Nowak S; Zukiel R; Nowak M; Piestrzeniewicz R; Gawrońska I; Barciszewska MZ; Barciszewski J
Acta Pol Pharm; 2008; 65(6):677-84. PubMed ID: 19172848
[TBL] [Abstract][Full Text] [Related]
30. Hypericin uptake: a prognostic marker for survival in high-grade glioma.
Ritz R; Müller M; Dietz K; Duffner F; Bornemann A; Roser F; Tatagiba M
J Clin Neurosci; 2008 Jul; 15(7):778-83. PubMed ID: 18394904
[TBL] [Abstract][Full Text] [Related]
31. Local administration of interferon for malignant brain tumors.
Nakagawa Y; Hirakawa K; Ueda S; Suzuki K; Fukuma S; Kishida T; Imanishi J; Amagai T
Cancer Treat Rep; 1983 Sep; 67(9):833-5. PubMed ID: 6688376
[TBL] [Abstract][Full Text] [Related]
32. Formulation and antitumor efficacy of liposomal-caprylated-TNF-SAM2.
Akimaru K; Auzenne E; Akimaru Y; Leroux ME; Hayman AC; Utsumi T; Soma G; Klostergaard J
Cytokines Mol Ther; 1995 Sep; 1(3):197-210. PubMed ID: 9384676
[TBL] [Abstract][Full Text] [Related]
33. Recombinant human tumor necrosis factor causes regression in patients with advanced malignancies.
Watanabe N; Yamauchi N; Maeda M; Neda H; Tsuji Y; Okamoto T; Tsuji N; Akiyama S; Sasaki H; Niitsu Y
Oncology; 1994; 51(4):360-5. PubMed ID: 8208522
[TBL] [Abstract][Full Text] [Related]
34. A long-term survivor case of malignant mesothelioma treated by recombinant tumor necrosis factor-SAM2 (TNF-alpha mutein) and 5-fluorouracil (5-FU): a new therapeutic approach based on host-tumor relationship.
Takagi K; Fukushima Y; Kanou J; Honda T; Tomita K; Takano M; Soma G
Anticancer Res; 1998; 18(6B):4591-600. PubMed ID: 9891524
[TBL] [Abstract][Full Text] [Related]
35. Clinical effect of intra-arterial tumor necrosis factor-alpha for malignant glioma.
Yoshida J; Wakabayashi T; Mizuno M; Sugita K; Yoshida T; Hori S; Mori T; Sato T; Karashima A; Kurisu K
J Neurosurg; 1992 Jul; 77(1):78-83. PubMed ID: 1607975
[TBL] [Abstract][Full Text] [Related]
36. Complete regression of anaplastic astrocytoma by intravenous tumor necrosis factor-alpha (TNF alpha) after recurrence: a case report.
Maruno M; Yoshimine T; Nakata H; Nishioka K; Kato A; Hayakawa T
Surg Neurol; 1994 Jun; 41(6):482-5. PubMed ID: 8059327
[TBL] [Abstract][Full Text] [Related]
37. Hemodynamic evaluation of recombinant human tumor necrosis factor (TNF)-alpha, TNF-SAM2 and liposomal TNF-SAM2 in an anesthetized dog model.
Lodato RF; Feig B; Akimaru K; Soma G; Klostergaard J
J Immunother Emphasis Tumor Immunol; 1995 Jan; 17(1):19-29. PubMed ID: 7728303
[TBL] [Abstract][Full Text] [Related]
38. Application of intraoperative radiotherapy for malignant glioma.
Ji X; Ding W; Wang J; Zhou B; Li Y; Jiang W; Pan H; Gu J; Sun X
Cancer Radiother; 2023 Sep; 27(5):425-433. PubMed ID: 37344258
[TBL] [Abstract][Full Text] [Related]
39. [1st results of experimental use of cobalt 60 in frontal lobe of rabbit; experimental induction of a malignant cerebral glioma].
JENTZER A
Confin Neurol; 1959; 19(3):264-9. PubMed ID: 13652536
[No Abstract] [Full Text] [Related]
40. The Use of Targeted Cytokines as Cancer Therapeutics in Glioblastoma.
Sooreshjani M; Tripathi S; Dussold C; Najem H; de Groot J; Lukas RV; Heimberger AB
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
